Authors say insurance barrier poses risks to safety, health, and well-being
TUESDAY, Nov. 17, 2020 (HealthDay News) — Lack of insurance coverage for gender-affirming hormones is associated with a lower likelihood of hormone use and higher odds of use of nonprescription hormones among transgender adults, according to a study published in the November issue of the Annals of Family Medicine.
Daphna Stroumsa, M.D., from the University of Michigan in Ann Arbor, and colleagues used data from the U.S. Transgender Survey (August to September 2015) to evaluate associations between insurance coverage for gender-affirming hormones and patterns of hormone use.
The researchers found that among 12,037 transgender adults using hormones, 9.17 percent were using nonprescription hormones. More than one in five insured respondents (20.81 percent) reported that their claims were denied. Respondents who were uninsured (odds ratio, 2.64) or whose claims were denied (odds ratio, 2.53) were more likely to use nonprescription hormones. Hormone use was less likely among uninsured respondents (odds ratio, 0.37).
“Ensuring access to hormones can decrease the economic burden transgender people face, and is an important part of harm-reduction strategies,” the authors write.
Dense Breast Notification Linked to Increase in Use of Supplemental Ultrasound 
Workplace Psychological Stress Linked to Erectile Function in Young Men 
Adverse Pathological Features Do Not Predict Benefit of Hormone Therapy in Prostate Cancer 
Insurance Poses Barrier to Virtual Pulmonary Rehabilitation for COPD 
Use of SAMA, SABA Linked to Cardiovascular Events, Mortality in Asthma, COPD 
Higher Short-Term Exposure to Pollen Linked to Lower FEV1 in COPD 
Emergency Diagnosis Linked to Worse Outcomes for Range of Conditions 
Higher Diet Quality Linked to Improved Lung Function in Asthma, COPD 
